A Phase 3 interventional study of Andecaliximab and Placebo in Gastric Adenocarcinoma, sponsored by Gilead Sciences. Completed at 134 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-26.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 804 studies in Stomach Neoplasms with a site in United States — 157 open to participants now, 239 under way, 12 of them phase 3. Stomach Neoplasms · United States.
Among the 804 studies in Stomach Neoplasms with a site in United States, this one is the 57th largest by enrollment of the 686 interventional ones that give a count, is one of 24 that started in 2015, is one of 39 in phase 3, and was the 330th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →157 of the 804 studies in Stomach Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
University of Illinois Chicago · Sites in United States
Ages 18+
Sutro Biopharma, Inc. · Sites in United States
Ages 18+
MacroGenics · Sites in United States
Ages 18+
GE Healthcare · Sites in United States, Sweden
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
804 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 380 · Phase 2 338 · Phase 3 45 · Phase 4 10
First in 1992; this study’s year is marked. 24 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 432 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 53 across the 686 interventional studies, 207 across the 83 observational. Of the 512 that completed or were terminated, 196 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
381 of 804 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 1 study filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
81 of the studies in Stomach Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06532006Phase 3Shanghai Henlius BiotechA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | 2027-06-01 |
| NCT07217704Phase 3SOFIEUsing 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | 2027-08-30 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT06219941AstraZenecaAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | 2026-11-17 |
Add all 81 to your calendar (.ics) → With an account.
Among the 804 studies in Stomach Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Andecaliximab plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by andecaliximab plus LV+5-FU during subsequent cycles
Drug: Andecaliximab · Drug: Leucovorin · Drug: 5-fluorouracil · Drug: Oxaliplatin
Placebo plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by placebo plus LV+5-FU during subsequent cycles
Drug: Placebo · Drug: Leucovorin · Drug: 5-fluorouracil · Drug: Oxaliplatin
800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Also known as: GS-5745
Administered intravenously on Days 1 and 15 of each treatment cycle
Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Also known as: LV
Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Also known as: 5-FU
Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Also known as: OXA
Overall Survival (OS)
OS was defined as the time interval from the date of randomization to death from any cause.
Time frame: Andecaliximab + mFOLFOX6 median follow-up at the time of final analysis: 19.43 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 19.45 months
Progression-free Survival (PFS)
PFS was defined as the interval of time from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause.
Time frame: Andecaliximab + mFOLFOX6 median follow-up at the time of the final analysis: 18.64 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 18.74 months
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 135.4 weeks at the time of final analysis
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events in a given study period that meet any of the following criteria: Any AE with onset date of on or after andecalizimab/placebo start date and no later than 30 days after permanent discontinuation of all study treatment (andecaliximab/placebo and chemotherapy) or Any AEs with onset date of on or after the andecaliximab/placebo start date and no later than 55 days after permanent discontinuation of andecaliximab/placebo or AEs leading to discontinuation of andecaliximab/placebo.
Time frame: First dose date up to the last dose date (maximum:161.7 weeks) plus 30 to 55 days
Percentage of Participants With Clinically Relevant Treatment-emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to 30 days after the last dose of all study treatment, or 55 days after the last dose of andecaliximab/placebo for participants who permanently discontinued all study treatments. If the relevant baseline laboratory value is missing, then any abnormality of at least Grade 1 was considered treatment-emergent.
Time frame: First dose date up to the last dose date (maximum: 161.7 weeks) plus 30 to 55 days
Participants were enrolled at study sites in Australia, Europe, Chile, Colombia, Peru, Turkey, and the United States. The first participant was screened on 13 October 2015. The last study visit occurred on 15 May 2019.
| Milestone | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 |
|---|---|---|
| Started | 218 | 214 |
| Completed | 0 | 0 |
| Not completed | 218 | 214 |
| Withdrew: Death | 174 | 168 |
| Withdrew: Unknown reason | 30 | 32 |
| Withdrew: Withdrew consent | 9 | 11 |
| Withdrew: Investigator's discretion | 3 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 |
OS was defined as the time interval from the date of randomization to death from any cause.
| months | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 |
|---|---|---|
| Overall Survival (OS) | 12.52 (11.2 to 14.0) | 11.76 (10.3 to 13.5) |
PFS was defined as the interval of time from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause.
| months | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 |
|---|---|---|
| Progression-free Survival (PFS) | 7.46 (7.29 to 8.41) | 7.06 (5.52 to 7.46) |
ORR was defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 |
|---|---|---|
| Objective Response Rate (ORR) | 50.5 (43.6 to 57.3) | 41.1 (34.5 to 48.0) |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events in a given study period that meet any of the following criteria: Any AE with onset date of on or after andecalizimab/placebo start date and no later than 30 days after permanent discontinuation of all study treatment (andecaliximab/placebo and chemotherapy) or Any AEs with onset date of on or after the andecaliximab/placebo start date and no later than 55 days after permanent discontinuation of andecaliximab/placebo or AEs leading to discontinuation of andecaliximab/placebo.
| percentage of participants | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 |
|---|---|---|
| Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) | 99.1 | 99.5 |
Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to 30 days after the last dose of all study treatment, or 55 days after the last dose of andecaliximab/placebo for participants who permanently discontinued all study treatments. If the relevant baseline laboratory value is missing, then any abnormality of at least Grade 1 was considered treatment-emergent.
| percentage of participants | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 |
|---|---|---|
| Hematology | 94.4 | 89.5 |
| Serum Chemistry | 91.7 | 92.9 |
| Coagulation | 7.4 | 3.3 |
Collected over All-Cause Mortality: First dose date up to 42 months; Adverse Events: First dose date up to the last dose date (maximum: 161.7 weeks) plus 30 to 55 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Andecaliximab + mFOLFOX6 | 174/218 (79.8%) | 103/216 (47.7%) | 209/216 (96.8%) |
| Placebo + mFOLFOX6 | 168/214 (78.5%) | 108/210 (51.4%) | 203/210 (96.7%) |
| Event | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 |
|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 8/216 | 13/210 |
| VomitingGastrointestinal disorders | 11/216 | 8/210 |
| Abdominal painGastrointestinal disorders | 7/216 | 8/210 |
| PneumoniaInfections and infestations | 7/216 | 5/210 |
| Obstruction gastricGastrointestinal disorders | 3/216 | 6/210 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/216 | 5/210 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 6/216 | 4/210 |
| DiarrhoeaGastrointestinal disorders | 3/216 | 5/210 |
| NeutropeniaBlood and lymphatic system disorders | 4/216 | 4/210 |
| Intestinal obstructionGastrointestinal disorders | 1/216 | 4/210 |
| Event | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 |
|---|---|---|
| NauseaGastrointestinal disorders | 106/216 | 118/210 |
| DiarrhoeaGastrointestinal disorders | 87/216 | 88/210 |
| FatigueGeneral disorders | 79/216 | 72/210 |
| NeutropeniaBlood and lymphatic system disorders | 76/216 | 73/210 |
| Decreased appetiteMetabolism and nutrition disorders | 63/216 | 72/210 |
| Peripheral sensory neuropathyNervous system disorders | 73/216 | 72/210 |
| AnaemiaBlood and lymphatic system disorders | 61/216 | 62/210 |
| VomitingGastrointestinal disorders | 63/216 | 62/210 |
| ConstipationGastrointestinal disorders | 61/216 | 61/210 |
| AstheniaGeneral disorders | 62/216 | 52/210 |
The Intent-to-Treat (ITT) Analysis Set included all randomized participants.
| Age, Continuous(years) | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 | Total |
|---|---|---|---|
| Mean | 60 ± 11.9 | 61 ± 11.4 | 60 ± 11.7 |
| Sex: Female, Male(Participants) | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 | Total |
|---|---|---|---|
| Female | 50 | 61 | 111 |
| Male | 168 | 153 | 321 |
| Race/Ethnicity, Customized(Participants) | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 1 | 1 |
| Race — Asian | 5 | 5 | 10 |
| Race — Black or African American | 4 | 4 | 8 |
| Race — White | 186 | 184 | 370 |
| Race — Not Permitted | 8 | 6 | 14 |
| Race — Other | 15 | 14 | 29 |
| Race/Ethnicity, Customized(Participants) | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 38 | 32 | 70 |
| Ethnicity — Not Hispanic or Latino | 170 | 173 | 343 |
| Ethnicity — Not Permitted | 10 | 9 | 19 |
| Region of Enrollment(Participants) | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 | Total |
|---|---|---|---|
| Colombia | 5 | 6 | 11 |
| Romania | 15 | 13 | 28 |
| Hungary | 11 | 15 | 26 |
| United States | 47 | 59 | 106 |
| Czechia | 10 | 5 | 15 |
| United Kingdom | 5 | 6 | 11 |
| Spain | 27 | 28 | 55 |
| Turkey | 17 | 18 | 35 |
| Belgium | 2 | 3 | 5 |
| Poland | 13 | 11 | 24 |
| Italy | 8 | 6 | 14 |
| Australia | 13 | 18 | 31 |
| Chile | 15 | 11 | 26 |
| France | 10 | 3 | 13 |
| Peru | 4 | 4 | 8 |
| Germany | 16 | 8 | 24 |
| Type of Cancer(Participants) | Andecaliximab + mFOLFOX6 | Placebo + mFOLFOX6 | Total |
|---|---|---|---|
| Gastric | 142 | 143 | 285 |
| Gastroesophageal junction | 76 | 71 | 147 |
Showing the first 100 of 134 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2015 to primary completion in May 2019, 43 months.
Results were first posted in Apr 2020, 11 months after primary completion.
Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 43 months is close to that.
Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Andecaliximab